The UK and US have forged a landmark trade agreement that will guarantee no levies on UK drug exports being sold in the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost spending on medicines through the National Health Service (NHS). This pledge guarantees that import taxes on these key exports will be held at nothing for a duration of the next three years.
This deal is in response to previous warnings to significantly raise tariffs on branded drug imports, with figures floated reaching 100%.
"This deal between the United Kingdom bolsters the international landscape for innovative medicines and introduces long-overdue balance to U.S.–U.K. drug exports," an announcement said.
Economic Significance
Pharmaceuticals represent one of the Britain's biggest export categories to the United States, which is clearly the primary destination for major UK drugmakers.
Export figures show that in the 12 months leading up to last September, the UK sold pharmaceutical products worth billions to the US. This value accounted for 17.4% of all goods exports in that span.
"This deal secures work, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments exceeded twenty percent.
Broader Context
The pact follows a ongoing dispute between the drug companies and the British authorities over medicine costs and NHS adoption.
This friction were exacerbated by claims that American customers were charged significantly more for the equivalent treatments than consumers in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while major expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to spend more on treatments, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the past decade.
